Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
暂无分享,去创建一个
Jules C Hancox | Derek J Leishman | Harry J Witchel | James T Milnes | J. Hancox | H. Witchel | D. Leishman | J. Leaney | J. Milnes | Joanne L Leaney
[1] J. Hancox,et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.
[2] Michael Markert,et al. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. , 2004, Journal of pharmacological and toxicological methods.
[3] G. Gintant. Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. , 2000, American journal of physiology. Heart and circulatory physiology.
[4] J. Hancox,et al. A method for making rapid changes of superfusate whilst maintaining temperature at 37°C , 1996, Pflügers Archiv.
[5] Gary A Gintant,et al. The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.
[6] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[7] W. Crumb,et al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. , 2004, Journal of pharmacological sciences.
[8] J. Hancox,et al. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability. , 2008, Pharmacology & therapeutics.
[9] A. Brown,et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. , 2004, Journal of pharmacological and toxicological methods.
[10] J. Wigle,et al. Intracellular K+ Is Required for the Inactivation-Induced High-Affinity Binding of Cisapride to HERG Channels , 2005, Molecular Pharmacology.
[11] E. Carmeliet. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. , 1992, The Journal of pharmacology and experimental therapeutics.
[12] J. Henney. Celecoxib Indicated for FAP , 2000 .
[13] Jules C Hancox,et al. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. , 2002, Journal of pharmacological and toxicological methods.
[14] Haruo Honjo,et al. Molecular determinants of hERG channel block by terfenadine and cisapride. , 2008, Journal of pharmacological sciences.
[15] Stanley Nattel,et al. Dofetilide block involves interactions with open and inactivated states of HERG channels , 2002, Pflügers Archiv - European Journal of Physiology.
[16] R. Baker,et al. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. , 2005, Journal of pharmacological and toxicological methods.
[17] Hao Wang,et al. Functional and pharmacological properties of canine ERG potassium channels. , 2003, American journal of physiology. Heart and circulatory physiology.
[18] T. Toga,et al. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. , 2007, Journal of pharmacological sciences.
[19] T J Campbell,et al. Inhibition of the human ether‐a‐go‐go‐related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states , 1999, British journal of pharmacology.
[20] Jiesheng Kang,et al. Cardiac Ion Channel Effects of Tolterodine , 2004, Journal of Pharmacology and Experimental Therapeutics.
[21] Anthony Varghese,et al. Effects of premature stimulation on HERG K+ channels , 2001, The Journal of physiology.
[22] A. Brown,et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.
[23] Qiuming Gong,et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.
[24] D. Fedida,et al. Rb+ Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb+ Efflux Assay , 2004, Journal of biomolecular screening.
[25] D. Escande,et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. , 2001, The Journal of pharmacology and experimental therapeutics.
[26] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Hancox,et al. hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. , 2006, Biochemical and biophysical research communications.
[28] H. Duff,et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.
[29] Jamie I Vandenberg,et al. Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels , 2008, Molecular Pharmacology.
[30] John S. Mitcheson,et al. Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.
[31] J. Hancox,et al. Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs , 2008, British journal of pharmacology.
[32] A. Camm,et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.
[33] J. Hancox,et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin , 2007, Biochemical pharmacology.
[34] D. Snyders,et al. High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.
[35] Jules C. Hancox,et al. The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C , 2005 .
[36] D. Rampe,et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.
[37] R. Shah,et al. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. , 2005, Novartis Foundation symposium.
[38] A. Brown,et al. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.
[39] Y. Kawabata,et al. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. , 2004, European journal of pharmacology.
[40] J. Hancox,et al. Lidoflazine is a high affinity blocker of the HERG K(+)channel. , 2004, Journal of molecular and cellular cardiology.
[41] Todd Wisialowski,et al. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.
[42] Gary A Gintant,et al. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. , 2008, Pharmacology & therapeutics.
[43] W. Crumb,et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.
[44] Rui Wang,et al. Endogenous KV channels in human embryonic kidney (HEK-293) cells , 2002, Molecular and Cellular Biochemistry.
[45] Martyn P Mahaut-Smith,et al. Temperature dependence of human ether-a-go-go-related gene K+ currents. , 2006, American journal of physiology. Cell physiology.
[46] State dependent dissociation of HERG channel inhibitors , 2007 .
[47] Jules C Hancox,et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.
[48] D. Roden,et al. IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[50] G. Gintant,et al. ALTERING EXTRACELLULAR POTASSIUM CONCENTRATION DOES NOT MODULATE DRUG BLOCK OF HUMAN ETHER‐A‐GO‐GO‐RELATED GENE (hERG) CHANNELS , 2006, Clinical and experimental pharmacology & physiology.
[51] Kaichiro Kamiya,et al. Molecular Determinants of hERG Channel Block , 2006, Molecular Pharmacology.
[52] J. Henney. New Inhaled Corticosteroid , 2000 .
[53] Jules C Hancox,et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin , 2006, British journal of pharmacology.
[54] A. Bass,et al. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. , 2005, Journal of pharmacological and toxicological methods.
[55] A. Camm,et al. Drug induced QT prolongation and torsades de pointes , 2003, Heart.
[56] Harry J. Witchel,et al. Time course and voltage dependence of expressed HERG current compared with native ”rapid” delayed rectifier K current during the cardiac ventricular action potential , 1998, Pflügers Archiv.
[57] J. Hancox,et al. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. , 2006, Journal of molecular and cellular cardiology.